Showing results (481-490 of 587) with videos related to

Sort By:
Pageof 59
Cancer Discovery|June 28, 2023
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial CancerFrancesco Facchinetti, Antoine Hollebecque, Floriane Braye, et al.
The New England Journal of Medicine|October 17, 2025
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLCPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentJames Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 6, 2025
Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC NetworksSarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, et al.
Translational Lung Cancer Research|August 13, 2025
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile studyEdouard Auclin, Pauline Du Rusquec, Victor Albarran-Artahona, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2022
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohortSimon Baldacci, Benjamin Besse, Virginie Avrillon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 1, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLCPasi A Jänne, Yasushi Goto, Toshio Kubo, et al.
Translational Lung Cancer Research|May 20, 2021
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancerVictoria Foy, Colin R Lindsay, Alexandra Carmel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2021
Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 TrialVivek Subbiah, Justin F Gainor, Geoffrey R Oxnard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung CancersAlexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Pageof 59